Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04282980 | A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) | PHASE2 | COMPLETED | 39 | — | — | Apr 23, 2020 | Aug 23, 2022 | Mar 3, 2025 | 9 | China |
Progression-Free Survival (PFS) is defined as the time from the first dose of study drug to the first occurrence of disease progression based on independent radiology review or death due to any cause (whichever occurred first).
| Arm | Type | Description |
|---|---|---|
| DCC-2618 | EXPERIMENTAL | DCC-2618 drug is 50mg per tablet, 150mg once a day, with 28 days as a treatment cycle. |
| Name | Type | Description |
|---|---|---|
| DCC-2618 | DRUG | Oral kinase inhibitor |
Inclusion Criteria: * Male or female patients ≥18 years of age. * Patients with advanced gastrointestinal stromal tumors. * Subjects who have progressed or documented intolerance after previous treatments. * Sign informed consent, understand the Protocol and could follow the Protocol. * The subject...